Sign In
Free Newsletter
Kindred Biosciences to Present Pivotal Data on Zimeta
Pet Age Staff //November 29, 2016//
Listen to this articleKindred Biosciences, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, announced today that Emily Sundman, DVM, clinical development scientist for KindredBio, will present pivotal effectiveness data for Zimeta™ (dipyrone injection) at the American Association of Equine Practitioners (AAEP) Convention in Orlando, Florida, on Tuesday, December 6, 2016, at 8:25 a.m. ET as part of the Internal Medicine track. The presentation will be available at www.kindredbio.com/investor-relations/events/ following the AAEP presentation.
Zimeta is a pyrazolone anti-inflammatory drug with a unique mechanism of action that is under development for the control of pyrexia (fever) in horses. The application for Zimeta is currently under review at the FDA Center for Veterinary Medicine (CVM). Approval and launch of the drug is expected in 2017.
